Introduction
Although myb genes were ®rst discovered as retroviral oncogenes, it has proved extremely dicult to link mutation of the cellular proto-oncogene c-myb to most forms of human cancer. A survey of human lymphoid and myeloid tumors demonstrated that c-myb overexpression is common, but this may simply be a proliferation marker (Wol, 1996) . That c-myb expression is important for the continued proliferation of leukemic cells is suggested by antisense experiments, which argue that removing c-myb mRNA results in the death of the cells; indeed, antisense-mediated ablation of c-Myb has already been tested as a potential therapy for human leukemia (Gewirtz et al., 1998) .
If it could be shown that c-Myb increased its activity in response to an initiating oncogenic change, and that this activity was required for the subsequent development of tumors, c-Myb would be ®rmly in the cancer picture. However, eorts to provide this sort of evidence have been stymied by the frustrating inability precisely to place c-myb within the network of signal transduction pathways which have been elaborated in the past few years. Recent results from the Ness and Leutz laboratories have at least partially remedied this. Kowenz-Leutz et al. (1997) showed that the transcription factor activity of c-Myb could be modi®ed in response to upstream kinase signaling pathways, allowing it to interact with dierent sets of oncogenically relevant target genes, and Leverson et al. (1998) demonstrated that this signal could be transmitted to cMyb via the transcriptional co-activator p100 interacting with the serine-threonine kinase Pim-1. The involvement of Pim-1 is especially provocative, as it puts c-Myb activation downstream of several cytokine signaling pathways. Furthermore, it has been known for a number of years that Pim-1 synergizes strongly with c-Myc in the induction of lymphoid and other hematopoietic malignancies in mice. It is possible that in these tumors, deregulated Pim-1 activates c-Myb, and this is important for the action of Pim-1 as an oncogene. This review will assess the likelihood that this may happen, and whether Myb and Myc are hitherto unrecognized collaborators in the formation of hematopoietic tumors.
The perfect couple -pim-1 and c-myc
One of the most useful systems for isolating new oncogenes and establishing their potential partners in tumorigenesis has been proviral tagging in mice. The most frequently used method, pioneered by Berns and colleagues (for review, see Jonkers and Berns, 1996) , is to inject neonatal mice with high titre Moloney murine leukemia virus (M-MuLV). On its own, M-MuLV causes T cell lymphomas with a latency of a few months, by integrating near to proto-oncogenes and in the majority of cases, transcriptionally activating them. When used to infect neonatal transgenic mice already expressing a weak oncogene, M-MuLV often acts as an accelerator of lymphomagenesis; genes which have contributed to this acceleration can be subsequently cloned using the M-MuLV sequence as a tag. It was in this system that the c-myc and pim-1 genes were ®rst shown to cooperate. C-myc was already known to be over-expressed in the vast majority of retrovirusinduced lymphomas in cats, birds and mice (reviewed in Kung et al., 1991) , and was therefore thought to be an important factor in lymphomagenesis. The pim-1 gene, ®rst identi®ed as a site of integration in retrovirally-induced murine T cell lymphomas (Cuypers et al., 1984) , has weak oncogenic activity when expressed as a transgene (Em-pim1) in a lymphoidspeci®c fashion. However, this activity can be greatly enhanced by neonatal M-MuLV infection. In every accelerated lymphoma, c-or N-myc were shown to be the integration targets of the M-MuLV (van Lohuizen et al., 1989) . Crossing the Em-pim1 transgenic strain to Em-myc mice, which express c-myc in their B lymphoid lineage, produced pre-B cell leukemias prenatally . Subsequent experiments have shown that L-myc and N-myc can also synergize strongly with pim-1 (Moroy et al., 1991) , and also that pim-2 and pim-3 can synergize with c-myc Allen et al., 1997; van der Lugt et al., 1995) .
Many further experiments using this insertional mutagenesis technique have identi®ed a number of loci which are able to cooperate with pim-1 and/or Myc. The fact that certain combinations of activated oncogenes are highly favored, whilst others are rarely, if ever found, has also led to the proposal that cooperating oncogenes fall into complementation groups (Jonkers and Berns, 1996) . For example, Bmi-1, a mouse Polycomb group gene, is frequently found activated following M-MuLV infection of Em-myc transgenic mice, as is g®-1 (also known as pal-1), which encodes a zinc ®nger protein (Haupt et al., 1991; van Lohuizen et al., 1991) . In some tumors, both pim-1 and either bmi-1 or g®-1 were targets of proviral insertion, but insertions into the bmi-1 and g®-1 loci were never found together. In support of this, bmi-1 transgenics infected with M-MuLV never contain a mutated g®-1 allele (Alkema et al., 1997) . It is therefore possible that these two genes are acting on the same pathway to transformation.
Complementation of the defects of oncogenic c-myc
Deregulating a proto-oncogene presumably means that a rate-limiting step to tumorigenesis has been overcome. It follows from this that synergizing oncogenes deregulate dierent rate-limiting steps. Although the idea that separate oncogenes aect separate processes such as cell death, the cell cycle or dierentiation is clearly naõÈ ve, it is certainly possible that the deregulation of one process is most important in the ability of an oncogene to cause tumors. This is perhaps the case with c-myc, which when over-expressed can drive cells into cycle whilst also causing apoptosis (Eilers et al., 1989; Evan et al., 1992) . As the former is a good thing for a tumor, but the latter is not, oncogenes capable of cooperating with c-myc might therefore be those which could rescue cells from death. Indeed, it is well known that c-myc and the anti-apoptotic protein bcl-2 can synergize both in tissue culture and in mouse models of tumorigenesis (McDonnell and Korsmeyer, 1991; Strasser et al., 1990; Vaux et al., 1988) . However, enhanced protection from death is still insucient for c-myc-driven tumors to form, as c-myc/bcl-2 tumors, like all others, are always mono-or oligo-clonal. It is evident that a range of variable and generally uncharacterized further mutations aecting other processes must occur during progression from the normal to the neoplastic state; many of the oncogenic partners of c-myc may exert their eects in this gray area.
Why might pim genes be such eager collaborators with c-myc? This question is currently rather hard to answer, as little is known about the non-neoplastic eects of pim-1 overexpression. There is some evidence from experiments in tissue culture that pim-1 can partially protect cells from apoptosis (Domen et al., 1993c; Lilly and Kraft, 1997; Moroy et al., 1993) , and will induce clonogenic expansion in IL-3-deprived FDC-P1 cells (Lilly and Kraft, 1997) . Mice de®cient in pim-1 expression have been generated (Laird et al., 1993) , but have little or no phenotype in vivo, presumably because pim-2 and pim-3 can compensate for the loss of pim-1 . In vitro, there are defects in proliferative responses to IL-3 and IL-7 (Domen et al., 1993a,b,c) . Conversely, analysis of Em-pim transgenics shows an enhancement in the size of IL-7-dependent early B cell compartments correlated with the degree of overexpression of the transgene (Domen et al., 1993a) . This increase in immature cell number correlates with a loss of more mature cells, implying that overexpressing pim-1 may cause a dierentiation block. During T cell development, the Em-pim transgene also causes changes in early thymopoiesis, apparently increasing the number of cycling cells at the b-selection stage (Schmidt et al., 1998) . However, there was no obvious decrease in the numbers of more mature thymocytes. Precisely why pim genes should be such eective partners for myc genes therefore remains obscure; by some means, perhaps by a dierentiation block, pim-1 may maintain a population of target cells which c-myc might then force into uncontrolled cycling. However, this is probably too simplistic, as pim-1 activation is not necessarily an early event in tumorigenesis. Although Em-pim transgenic mice are clearly predisposed towards developing tumors, implying that pim-1 overexpression establishes a preneoplastic state, it is also true that in some M-MuLV-accelerated tumors, pim-1 activation is a late event, contributing to the propagation of the tumor in syngeneic hosts (Feldman et al., 1997; Jonkers et al., 1997) . It could be that in these circumstances, protection from death might be more important.
The uncooperative c-myb gene
One proto-oncogene noticeably missing from the tally of those activated by neonatal infection with M-MuLV is of course c-myb. Two integration loci, ahi-1 and mis-2, have been localized to within 35 and 160 kb respectively of the 3' end of the c-Myb gene (Jiang et al., 1994; Villeneuve et al., 1993) , but there is no evidence for mutation of either locus causing increased expression of c-myb.
There are many reasons that an oncogene is not necessarily detectable by insertional mutagenesis. The most obvious, that its activation requires more than the simple overexpression and/or truncation method favored by retroviral insertion, clearly does not apply to c-myb, as it can be activated by M-MuLV in another context. When pristane-primed adult mice are infected with M-MuLV, promonocytic leukemias are induced within about 3 months in 100% of the mice, and all contain an activating integration within the c-myb gene, leading to the overexpression of a truncated oncogenic product (Wol, 1996) . Tissue speci®city of transformation is also not the excuse; in a transgenic model, the v-myb oncogene is capable of weakly transforming T cells when expressed in a T cell speci®c fashion, generating slow onset lymphomas with a latency of over a year . The very slowness of mybmediated transformation might be why c-myb integrations are never detected; M-MuLV tumors have a mean age of onset of around 4 ± 7 months, dependent on mouse strain, and any cells carrying cmyb integrations would be swamped out by their more tumorigenic neighbors. In support of this, transgenic mice expressing bcl-2 in their T lymphoid lineages develop low penetrance slow onset peripheral T cell lymphomas (Linette et al., 1995; Shinto Reassessing the role of C-MYB in tumorigenesis K Weston et al., 1995): bcl-2 is another oncogene never found activated in M-MuLV tumors.
The role of c-myb as an oncogene
The oncogenic activity of deregulated c-myb might depend upon any of its known properties: it is a survival factor, and it can inhibit myeloid and erythroid dierentiation, whilst permitting blocked immature cells to continue to divide (reviewed in Weston, 1998) . It is possible that each of these properties has dierent prominence in dierent cell types; indeed, the wide discrepancy between tumor onset times in dierent tissues indicates that this may be true. In myeloid cells and perhaps in the B lymphoid lineage (Pizer and Humphries, 1989) , where c-myb-induced tumorigenesis is relatively rapid, the ability to block dierentiation might be key; in contrast, in the T lymphoid lineage, where there is no evidence for a myb-mediated block to differentiation , but where Myb proteins can act as survival factors, regulating expression of bcl-2 (Taylor et al., 1996) , tumors are of slow onset, and survival of a pool of cells which can act as a target for another oncogene might be of primary importance.
Can c-myb cooperate with c-myc?
If c-myb requires its partners in oncogenic crime to compensate for its own de®ciencies, the c-myb gene might seem an ideal candidate. As described above, it can act as a survival factor, and it can also produce a pool of immature cells unable to dierentiate. Until now, the possible cooperativity of these two genes has not been investigated in animal models. Overexpression of c-myc mRNA was detected in the promonocytic leukemias generated by pristane-priming and M-MuLV insertional activation of c-myb (Mushinski et al., 1983) , but whether this contributed to the generation or propagation of the tumors is not known. However, the two genes do appear to cooperate during T lymphomagenesis. The transgenic mice described earlier, which overexpress v-Myb in their T cell lineages , develop T cell lymphomas roughly ®ve times faster when they are infected neonatally with M-MuLV. In 73% of the lymphomas obtained, insertional activation of either N-or c-myc had occurred (Davies, Badiani and Weston, unpublished) . The data closely resemble those generated when Em-bcl-2 animals are infected with M-MuLV, and it is therefore of great interest to determine whether overexpression of v-Myb protects lymphocytes and indeed other hematopoietic cells from c-myc induced apoptosis, perhaps at least partly via upregulation of its target gene bcl-2 (Frampton et al., 1996; Taylor et al., 1996) .
If Myb proteins are at least capable of cooperating with c-myc, is this important for human tumors? In many hematopoietic neoplasms, both c-myb and c-myc are co-ordinately overexpressed (Baer et al., 1992; Slamon et al., 1984) . Abrogation of the activity of either gene by antisense technology appears to reduce the viability of cells (reviewed in Gewirtz et al., 1998), so perhaps cooperation, at least in the maintenance of the tumors, is indeed taking place.
Does myb lie downstream of pim-1?
If one combined our recent data showing that myb and myc can cooperate, with the results linking pim-1 signaling to c-Myb activation (Leverson et al., 1998) , it seems possible that c-myb might lie downstream of pim-1 in tumorigenesis. At this point, it is impossible to predict the precise nature of the relationship between the two genes. Pim-1 is a good candidate as an important activator of c-Myb in both normal and tumorigenic hematopoietic cells. Like c-myb, pim-1 is widely expressed during hematopoiesis (Amson et al., 1989) and is an immediate early gene, induced by JAK activation in response to a wide range of cytokines (Damen et al., 1995; Dautry et al., 1988; Lilly et al., 1992; Miura et al., 1994; Mui et al., 1996; Quelle et al., 1996; Sakai and Kraft, 1997; Sato et al., 1993) . Mutations of any components in the multiple pathways leading to JAK activation would all cause increases in pim-1 expression, which in turn would super-activate c-Myb protein. However, it would be unrealistic to propose that activation of c-myb is the one important downstream target of pim-1 for a number of reasons. If it were, overexpression of vmyb should have had the same eect on T cells as the Em-pim-1 transgene, and c-myb should have appeared as an integration target in MuLV acceleration experiments; neither of these assertions is true. Through its association with the coactivator p100, Pim-1 protein probably aects the activity of a number of other transcription factors, and p100 itself is likely to be only one of many pim-1 targets. However, despite these caveats, it is possible that activation of c-Myb is necessary but not sucient for the oncogenic activity of pim-1. To address this question, experiments to determine whether dominant negative mutants of cMyb can block the cooperation of pim-1 with other oncogenes are currently underway in our laboratory.
Can Pim-1 convert c-Myb into an oncogene?
Just as c-Myb activation may not be the sole factor in pim-1-mediated transformation, Pim-1 expression may not be sucient to oncogenically activate c-Myb. The activity of c-Myb protein is tightly regulated at all levels, and many of these regulatory limitations have been lost in the original avian v-Myb oncoprotein: cmyb mRNA is short-lived and is only made during G1 phase of the cell cycle in many cell types (reviewed in Weston, 1998) , whilst v-myb mRNA must be overexpressed for transformation to occur (Schirm et al., 1990) ; c-Myb protein is also short-lived, whilst v-Myb is not (Bies and Wol, 1997) ; c-Myb contains binding sites for a number of negative regulatory molecules, most of which do not bind v-Myb (Ness, 1999) , and ®nally, the truncations found in the v-Myb oncogene aect regions of the protein involved in its phosphorylation by kinases other than Pim-1 (Aziz et al., 1993; Luscher et al., 1990) . In mice, the minimal requirements for oncogenic activation of c-Myb appear to be overexpression coupled to an increase in the anity of the protein for DNA (reviewed in Wol, 1996) . Pim-1 could aect the latter, but it is unlikely to be able to aect c-myb overexpression. However, an intriguing possibility is that as pim-1 and c-myb are induced with identical kinetics in response to IL-2 (Dautry et al., 1988; Rohwer et al., 1996) , and may respond similarly to other cytokines, some oncogenic mutations which activate cytokine signaling pathways may coordinately up-regulate both genes. A mutated ras gene, a frequent event in human tumors, might well be such a stimulus. Fortunately, all these points can be resolved relatively quickly by straightforward experiments, so an end to speculation may be in sight.
Conclusions
The simple assays employed in the past to determine whether c-myb is either rearranged or overexpressed in human tumors will have failed to detect either more subtle deregulating mutations, or whether a wild-type c-Myb protein is aberrantly activated. Perhaps then, it is merely the assays which have been at fault, rather than the inability of c-myb to act as a human oncogene. Indeed, it has always been a matter of puzzlement that every other avian retroviral oncogene except v-myb has been shown to play a role in mammalian tumorigenesis. In the light of the new data placing c-Myb activation downstream of signal transduction cascades already implicated in human cancer, it seems that the time has come to re-assess the role played by c-Myb in hematopoietic neoplasms. A screen of a human tumor panel, looking for point mutations such as those found in AMV v-myb, which might allow the c-Myb protein to evade its normal negative regulatory mechanisms (Kowenz-Leutz et al., 1997), would be timely. With suitable tools, we can ®nd out not only if pim-1 overexpression in tumors can induce super-activation of c-Myb, but whether other kinase oncoproteins have the same eect. The prospects for c-myb to become a villain have never been brighter.
